Social News
Written by: Cao Jiajun
2021-01-13 05:26
Last update date: 2021-01-13 05:26
According to clinical test data published by the Butantan Institute in Brazil on January 12, the "overall effective rate" of the new coronavirus pneumonia (COVID-19) vaccine developed by Sinovac is only 50.4%.
China Kexing is one of the three vaccines that the Hong Kong government announced earlier to purchase. The so-called "inactivated vaccine" developed by it means that the virus is killed through inactivation technology and filtered until it will not cause disease, thereby causing the human body Immune response.
"Inactivated vaccine" is a more traditional vaccine technology.
Its storage conditions are relatively simple. It only needs to be placed at 2 to 8 degrees under a regular refrigerator temperature. Many vaccines such as rabies vaccines are all inactivated vaccines.
According to mainland media reports, Kexing’s factory operates 24 hours a day and can now produce hundreds of thousands of doses of new crown vaccine every day. With the completion of the second phase of the factory, the daily output will exceed one million doses and the annual production capacity will exceed 600 million doses.
The Kexing inactivated vaccine uses the new coronavirus (CZ strain) to inoculate Vero cells, which is made by virus culture, harvest, inactivation, purification and aluminum adsorption, without adding preservatives and biological protective agents.
▼Kexing vaccine needs seven major steps from the laboratory to the market▼
+9
+9
+9
Price and side effects
As for other aspects such as price and side effects, Kexing Biosciences earlier assisted the government in launching the emergency use of the new crown vaccine in Yiwu, Jiaxing, Zhejiang and other places. Each dose was 200 yuan for a total of two doses.
It can be seen from the instructions on the vaccination informed consent form that adverse reactions are divided into three types: common adverse reactions, rare adverse reactions and extremely rare adverse reactions.
Common adverse reactions include pain, tenderness, redness, swelling, and itching at the injection site, or transient fever reactions; rare adverse reactions include severe redness and swelling at the injection site, severe fever reactions; extremely rare adverse reactions include local aseptic suppuration, allergies Sexual rash, anaphylactic shock, etc.
▼Protection rate side effects of Kexing, BioNTECH Fosun, AstraZeneca ▼
+2
+2
+2
According to the clinical test data published by the Brazilian Butantan Institute, the "overall effective rate" of the new coronavirus pneumonia vaccine developed by China Kexing Biotechnology is only 50.4%.
Ricardo Palacios, who is in charge of clinical research at the Brazilian Butantan Institute, which is Coxing’s local partner, said that the new data includes “very mild” infections that do not require treatment.
The Hong Kong government stated earlier (8th) that before the start of injections in Hong Kong, pharmaceutical companies must provide the third phase clinical study data, production process and other information for application, and the Department of Health has contacted Kexing, hoping to obtain the vaccine CoronaVac in Brazil Perform clinical test data for evaluation.
New Coronary Pneumonia | Brazil Butantan Institute: The effective rate of Coxing vaccine is only over 50%
Covid-19 vaccine | Thailand will allocate more than 300 million yuan to purchase China Kexing vaccine
New Coronary Pneumonia｜Indonesia Approves the Use of Koxing Vaccine "First Country" Outside China
Kexing vaccine effective rate is 78%. Department of Health: is requesting vaccine clinical test data for evaluation
01News
Vaccine Covid-19 Vaccine Vaccine Covid-19